TY - JOUR
T1 - Early Outcomes of SARS-CoV-2 Infection in a Multisite Prospective Cohort of Inpatient Veterans
AU - EPIC Investigators
AU - Ross, Jennifer M.
AU - Sugimoto, Jonathan D.
AU - Timmons, Andrew
AU - Adams, Jonathan
AU - Deardoff, Katrina
AU - Korpak, Anna
AU - Liu, Cindy
AU - Moore, Kathryn
AU - Wilson, Deanna
AU - Bedimo, Roger
AU - Chang, Kyong Mi
AU - Cho, Kelly
AU - Crothers, Kristina
AU - Garshick, Eric
AU - Gaziano, J. Michael
AU - Holodniy, Mark
AU - Hunt, Christine M.
AU - Isaacs, Stuart N.
AU - Le, Elizabeth
AU - Jones, Barbara E.
AU - Shah, Javeed A.
AU - Smith, Nicholas L.
AU - Lee, Jennifer S.
AU - Roghmann, Mary Claire
AU - Coffey, Karen
AU - Katzel, Les
AU - Wan, Emily
AU - Perez, Federico
AU - Jump, Robin
AU - Manaktala, Rohit
AU - Nicholson, Lindsay
AU - McClain, Micah
AU - Woods, Christopher
AU - Wang, Gary
AU - Vittor, Amy
AU - Theus, John
AU - Arkansas, North
AU - Mahatme, Sheran
AU - Gundacker, Milwaukee Nathan
AU - Haque, Milwaukee Javeria
AU - Paintal, Milwaukee Harman
AU - Stevenson, Matthew
AU - Baker, Joshua
AU - Pfeiffer, Chris
AU - Powers, Patrick
AU - Lewis, Julia
AU - Danaher, Patrick
AU - Anzueto, Antonio
AU - Eastment, McKenna
N1 - Publisher Copyright:
© 2023 Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2023/7/1
Y1 - 2023/7/1
N2 - Background: Over 870 000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have occurred among Veterans Health Administration users, and 24 000 have resulted in death. We examined early outcomes of SARS-CoV-2 infection in hospitalized veterans. Methods: In an ongoing, prospective cohort study, we enrolled veterans age ≥18 tested for SARS-CoV-2 and hospitalized at 15 Department of Veterans Affairs medical centers between February 2021 and June 2022. We estimated adjusted odds ratios (aORs), adjusted incidence rate ratios (aIRRs), and adjusted hazard ratios (aHRs) for maximum illness severity within 30 days of study entry (defined using the 4-category VA Severity Index for coronavirus disease 2019 [COVID-19]), as well as length of hospitalization and rehospitalization within 60 days, in relationship with demographic characteristics, Charlson comorbidity index (CCI), COVID-19 vaccination, and calendar period of enrollment. Results: The 542 participants included 329 (61%) who completed a primary vaccine series (with or without booster; "vaccinated"), 292 (54%) enrolled as SARS-CoV-2-positive, and 503 (93%) men, with a mean age of 64.4 years. High CCI scores (≥5) occurred in 61 (44%) vaccinated and 29 (19%) unvaccinated SARS-CoV-2-positive participants. Severe illness or death occurred in 29 (21%; 6% died) vaccinated and 31 (20%; 2% died) unvaccinated SARS-CoV-2-positive participants. SARS-CoV-2-positive inpatients per unit increase in CCI had greater multivariable-adjusted odds of severe illness (aOR, 1.21; 95% CI, 1.01-1.45), more hospitalization days (aIRR, 1.06; 95% CI, 1.03-1.10), and rehospitalization (aHR, 1.07; 95% CI, 1.01-1.12). Conclusions: In a cohort of hospitalized US veterans with SARS-CoV-2 infection, those with a higher CCI had more severe COVID-19 illness, more hospital days, and rehospitalization, after adjusting for vaccination status, age, sex, and calendar period.
AB - Background: Over 870 000 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections have occurred among Veterans Health Administration users, and 24 000 have resulted in death. We examined early outcomes of SARS-CoV-2 infection in hospitalized veterans. Methods: In an ongoing, prospective cohort study, we enrolled veterans age ≥18 tested for SARS-CoV-2 and hospitalized at 15 Department of Veterans Affairs medical centers between February 2021 and June 2022. We estimated adjusted odds ratios (aORs), adjusted incidence rate ratios (aIRRs), and adjusted hazard ratios (aHRs) for maximum illness severity within 30 days of study entry (defined using the 4-category VA Severity Index for coronavirus disease 2019 [COVID-19]), as well as length of hospitalization and rehospitalization within 60 days, in relationship with demographic characteristics, Charlson comorbidity index (CCI), COVID-19 vaccination, and calendar period of enrollment. Results: The 542 participants included 329 (61%) who completed a primary vaccine series (with or without booster; "vaccinated"), 292 (54%) enrolled as SARS-CoV-2-positive, and 503 (93%) men, with a mean age of 64.4 years. High CCI scores (≥5) occurred in 61 (44%) vaccinated and 29 (19%) unvaccinated SARS-CoV-2-positive participants. Severe illness or death occurred in 29 (21%; 6% died) vaccinated and 31 (20%; 2% died) unvaccinated SARS-CoV-2-positive participants. SARS-CoV-2-positive inpatients per unit increase in CCI had greater multivariable-adjusted odds of severe illness (aOR, 1.21; 95% CI, 1.01-1.45), more hospitalization days (aIRR, 1.06; 95% CI, 1.03-1.10), and rehospitalization (aHR, 1.07; 95% CI, 1.01-1.12). Conclusions: In a cohort of hospitalized US veterans with SARS-CoV-2 infection, those with a higher CCI had more severe COVID-19 illness, more hospital days, and rehospitalization, after adjusting for vaccination status, age, sex, and calendar period.
KW - COVID-19
KW - comorbidity
KW - rehospitalization
KW - severity
KW - veteran
UR - http://www.scopus.com/inward/record.url?scp=85167513052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85167513052&partnerID=8YFLogxK
U2 - 10.1093/ofid/ofad330
DO - 10.1093/ofid/ofad330
M3 - Article
C2 - 37484899
AN - SCOPUS:85167513052
SN - 2328-8957
VL - 10
JO - Open Forum Infectious Diseases
JF - Open Forum Infectious Diseases
IS - 7
M1 - ofad330
ER -